大规模多中心研究验证醛酮还原酶家族1成员B10可作为检测肝细胞癌的常用血清标志物
本研究在三个独立医院连续纳入1244名参与者,评估血清AKR1B10作为肝细胞癌检测标志物的价值。探索队列显示HCC患者血清AKR1B10高于健康对照,训练队列确定最佳诊断截断值为267.9 pg/mL,验证队列确认了这些发现。AKR1B10在早期HCC和AFP阴性HCC中显示出诊断潜力,与AFP联合可提高诊断准确性。
要点
- 血清AKR1B10在HCC患者中升高,诊断HCC的AUC为0.896,优于AFP的0.816。
- AKR1B10在早期HCC和AFP阴性HCC中显示出诊断潜力,与AFP联合可提高诊断准确性。
- HCC患者术后1天血清AKR1B10显著下降,术后3天几乎恢复正常。
核心结论
- AKR1B10是检测HCC和早期HCC的有效血清标志物,诊断性能优于AFP。
研究设计与样本
- 队列研究,连续纳入来自三个独立医院的1244名参与者,包括HCC、健康对照、良性肝肿瘤、慢性乙型肝炎和肝硬化患者。
- 血清AKR1B10采用时间分辨荧光分析法检测,数据用于绘制受试者工作特征(ROC)曲线进行分析。
- AFP作为比较指标进行分析。
主要发现
- 探索性发现队列显示,HCC患者血清AKR1B10为1567.3 ± 292.6 pg/mL(n=69),高于健康对照的85.7 ± 10.9 pg/mL(n=66;P < 0.0001)。
- 519名参与者的训练队列得出最佳诊断截断值为血清AKR1B10 267.9 pg/mL。
- HCC versus 所有对照(健康对照+良性肝肿瘤+慢性乙型肝炎+肝硬化)的ROC曲线分析显示,血清AKR1B10的AUC为0.896,敏感性72.7%,特异性95.7%,优于AFP的AUC 0.816,敏感性65.1%,特异性88.9%。
- AKR1B10在早期HCC和AFP阴性HCC中显示出有希望的诊断潜力,AKR1B10与AFP联合较单独AKR1B10或AFP提高了HCC的诊断准确性。
- 522名参与者的验证队列证实了这些发现。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Aldo-keto reductase family 1 member B10 (AKR1B10) is a secretory protein overexpressed in hepatocellular carcinoma (HCC). We aimed to evaluate AKR1B10 as a serum marker for detection of HCC. Herein, we conducted a cohort study that consecutively enrolled 1,244 participants from three independent hospitals, including HCC, healthy controls (HCs), benign liver tumors (BLTs), chronic hepatitis B (CHB), and liver cirrhosis (LC). Serum AKR1B10 was tested by time-resolved fluorescent assays. Data were plotted for receiver operating characteristic (ROC) curve analyses. Alpha-fetoprotein (AFP) was analyzed for comparison. An exploratory discovery cohort demonstrated that serum AKR1B10 increased in patients with HCC (1,567.3 ± 292.6 pg/mL; n = 69) compared with HCs (85.7 ± 10.9 pg/mL; n = 66; P < 0.0001). A training cohort of 519 participants yielded an optimal diagnostic cutoff of serum AKR1B10 at 267.9 pg/mL. When ROC curve was plotted for HCC versus all controls (HC + BLT + CHB + LC), serum AKR1B10 had diagnostic parameters of the area under the curve (AUC) 0.896, sensitivity 72.7%, and specificity 95.7%, which were better than AFP with AUC 0.816, sensitivity 65.1%, and specificity 88.9%. Impressively, AKR1B10 showed promising diagnostic potential in early-stage HCC and AFP-negative HCC. Combination of AKR1B10 with AFP increased diagnostic accuracy for HCC compared with AKR1B10 or AFP alone. A validation cohort of 522 participants confirmed these findings. An independent cohort of 68 patients with HCC who were followed up showed that serum AKR1B10 dramatically decreased 1 day after operation and was nearly back to normal 3 days after operation. Conclusion: AKR1B10 is a potent serum marker for detection of HCC and early-stage HCC, with better diagnostic performance than AFP.
引用
- Ye X, Li C, Zu X, et al. A Large-Scale Multicenter Study Validates Aldo-Keto Reductase Family 1 Member B10 as a Prevalent Serum Marker for Detection of Hepatocellular Carcinoma. Hepatology. 2019. PMID: 30672601. doi:10.1002/hep.30519
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。